Want to see DHR full AI Analyst Report?
Revenue by Segment
Breaks down sales figures by business unit, revealing which areas are performing well and contributing most to overall company growth.Danaher’s revenue mix has structurally shifted—Environmental & Applied Solutions drops out of reporting while a newly visible Biotechnology business has become a material, growth-oriented contributor (bioprocessing strength and consumables momentum). Life Sciences shows resilient consumables but softer instrument demand, and Diagnostics is uneven: strong non‑respiratory product traction offset by a sharp respiratory seasonality and China pricing headwinds. Management expects these headwinds to abate by year‑end, with bioprocessing momentum and the Masimo deal driving mid‑single‑digit exit growth—though equipment revenue remains lumpy despite robust order trends.
Date | Life Sciences | Diagnostics | Environmental and Applied Solutions | Biotechnology |
|---|---|---|---|---|
Jun 30, 2026 | $1.88B | $2.47B | $0.00 | $1.92B |
Mar 31, 2026 | $1.74B | $2.42B | $0.00 | $1.80B |
Dec 31, 2025 | $2.08B | $2.72B | $0.00 | $2.03B |
Sep 30, 2025 | $1.79B | $2.46B | $0.00 | $1.80B |
Jun 30, 2025 | $1.78B | $2.31B | $0.00 | $1.85B |
Mar 31, 2025 | $1.68B | $2.45B | $0.00 | $1.61B |
Dec 31, 2024 | $2.03B | $2.64B | $0.00 | $1.87B |
Sep 30, 2024 | $1.78B | $2.36B | $0.00 | $1.65B |
Jun 30, 2024 | $1.77B | $2.26B | $0.00 | $1.71B |
Mar 31, 2024 | $1.75B | $2.53B | $0.00 | $1.52B |